KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm. 2026;40(1):56-60 / www.klinickafarmakologie.cz 60 PŘEHLEDOVÉ ČLÁNKY Mikrobiom a farmakoterapie: od mechanismů k důsledkům mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011;8(2):110-120. 10. Krautkramer KA, Fan J, Bäckhed F. Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol. 2021;19(2):77-94. 11. Lei W, Zhou K, Lei Y, et al. Gut microbiota shapes cancer immunotherapy responses. NPJ Biofilms Microbiomes. 2025;11(1):143. 12. Haiser HJ, Gootenberg DB, Chatman K, et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science. 2013;341(6143):295-298. 13. Roberts AB, Wallace BD, Venkatesh MK, et al. Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol. 2013;84(2):208-217. 14. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, et al. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570(7762):462-467. 15. Ruiz-Moreno AJ, Del Castillo-Izquierdo Á, Tamargo-Rubio I, et al. MicrobeRX: a tool for enzymatic-reaction-based metabolite prediction in the gut microbiome. Microbiome. 2025;13(1):78. 16. Okuda H, Ogura K, Kato A, et al. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther. 1998;287(2):791-799. 17. Anzenbacher P, Anzenbacherová E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci. 2001; 58(5–6):737-747. 18. Hakkola J, Hukkanen J, Turpeinen M, et al. Inhibition and induction of CYP enzymes in humans: an update. Arch Toxicol. 2020;94(11):3671-3722. 19. Jourová L, Anzenbacher P, Lišková B, et al. Colonization by non-pathogenic bacteria alters mRNA expression of cytochromes P450 in originally germ-free mice. Folia Microbiol (Praha). 2017;62(6):463-469. 20. Nieves KM, Hirota SA, Flannigan KL. Xenobiotic receptors and the regulation of intestinal homeostasis: harnessing the chemical output of the intestinal microbiota. Am J Physiol Gastrointest Liver Physiol. 2022;322(2):G268-G281. 21. Dvořák Z, Sokol H, Mani S. Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine. Trends Pharmacol Sci. 2020;41(12):900-908. 22. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev. 1997;29(4): 1129-1188. 23. Puccetti M, Pariano M, Wojtylo P, et al. Turning Microbial AhR Agonists into Therapeutic Agents via Drug Delivery Systems. Pharmaceutics. 2023;15(2):506. 24. Recharla N, Geesala R, Shi XZ. Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review. Nutrients. 2023;15(10):2275. 25. Jourova L, Satka S, Frybortova V, et al. Butyrate Treatment of DSS-Induced Ulcerative Colitis Affects the Hepatic Drug Metabolism in Mice. Front Pharmacol. 2022a;13:936013. 26. Jourova L, Anzenbacherova E, Dostal Z, et al. Butyrate, a typical product of gut microbiome, affects function of the AhR gene, being a possible agent of crosstalk between gut microbiome, and hepatic drug metabolism. J Nutr Biochem. 2022b;107:109042. 27. Matuskova Z, Anzenbacherova E, Vecera R, et al. Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats. PLoS One. 2014;9(2):e87150. 28. Jourova L, Anzenbacher P, Matuskova Z, et al. Gut microbiota metabolizes nabumetone in vitro: Consequences for its bioavailability in vivo in the rodents with altered gut microbiome. Xenobiotica. 2019;49(11):1296-1302. 29. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc. 2013;78(2):240-249. 30. Perez E, Lee CH, Petrof EO. A Practical Method for Preparation of Fecal Microbiota Transplantation. Methods Mol Biol. 2016;1476:259-267. 31. Porcari S, Benech N, Valles-Colomer M, et al. Key determinants of success in fecal microbiota transplantation: From microbiome to clinic. Cell Host Microbe. 2023;31(5):712-733. 32. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103. 33. Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104-108. 34. Zhu C, Wang Y, Zhu R, et al. Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer. Biomark Res. 2024;12(1):56. 35. Xia L, Zhu X, Wang Y, et al. The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect. Cancer Lett. 2024;598:217123. 36. Herman C, Bolyen E, Simard A, et al. Assessing microbiome engraftment extent following fecal microbiota transplant with q2-fmt. PLoS Comput Biol. 2025;21(7):e1013299. 37. Reynolds HM, Bettini ML. Early-life microbiota-immune homeostasis. Front Immunol. 2023;14:1266876. 38. Hudcovic T, Hermanova P, Kozakova H, et al. Priority order of neonatal colonization by a probiotic or pathogenic Escherichia coli strain dictates the host response to experimental colitis. Front Microbiol. 2024;15:1393732. 39. Estevinho MM, Yuan Y, Rodríguez-Lago I, et al. Efficacy and safety of probiotics in IBD: An overview of systematic reviews and updated meta-analysis of randomized controlled trials. United European Gastroenterol J. 2024;12(7):960-981. 40. Jourová L, Anzenbacher P. Léky a mikrobiom. In: Tlaskalová-Hogenová Helena, Eklová Danka a kol. (eds). Mikrobiom a zdraví. Praha: Grada; 2024. s. 372-381. 1. zdarma První kongres po ukončení studia zdarma Odborné časopisy se slevou 40 % 40% Zvýhodněné registrační poplatky na většinu kongresů 40% VÝHODY PRO LÉKAŘE DO 35 LET Využijte své výhody na www.solen.cz Vzděláváme, inspirujeme a propojujeme zdravotníky už čtvrt století.
RkJQdWJsaXNoZXIy NDA4Mjc=